October 2024
Preapproval Information Exchange in Radicular Leg Pain Associated with Lumbar Disc Herniation
A Pre-Approval Information Exchange (PIE) Webinar, sponsored by Ferring Pharmaceuticals, Inc.
SI-6603 is an investigational product being evaluated for the treatment of radicular leg pain associated with lumbar disc herniation. This pre-approval information exchange (PIE) presentation includes disease overview, an overview of SI-6603 including MOA and pivotal study data along with anticipated timing and access details.
This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.
This product is in the clinical evaluation state and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
October 2024
A CGRP Receptor Antagonist for the Acute Treatment of Migraine: Focus on Early Treatment
A Science & Innovation Webinar, presented by Abbvie.
One of the main goals of acute treatment of migraine is freedom from pain and associated symptoms without recurrence. It is therefore important that every person with migraine, regardless of migraine frequency, be offered a migraine specific treatment that has freedom from pain data, freedom from associated symptom data and evidence that the treatment can prevent a moderate to severe migraine attack. The objective for this webinar is to review the migraine disease state and phases of a migraine attack, and outline clinical data as a treatment option for the acute treatment of migraine.
October 2024
Rethinking Schizophrenia: Prioritizing Cognitive Symptoms in Schizophrenia Care
A Pre-Approval Information Exchange (PIE) Webinar, sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.
Join a comprehensive webinar that will enhance your decision-making for people living with schizophrenia. This webinar will delve into a disease overview of schizophrenia, shedding light on the often overlooked cognitive symptom domain and its significant clinical and economic burden. The webinar will also uncover the latest understanding of the biological mechanisms and explore a potential new treatment approach to specifically target cognitive symptoms associated with schizophrenia.
This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®. This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
October 2024
AMCP Nexus 2024
- Call for Session Proposals - submission portal opens Mar. 18, 2024
- Call for Poster Abstracts - submission portal opens Mar. 18, 2024
- Registration opens Jul. 9, 2024 for members, Jul. 11, 2024 for all
October 2024
Nexus 2024 Pre-Conference Programs
Residency Program Design and Conduct
The Residency Program Design and Conduct Preconference program has been designed to review the newly developed and harmonized PGY1 Competency Areas, Goals, and Objectives (CAGOs) that went into effect July 2024 and align with the accreditation standards implemented in July 2023 for the design and conduct of a PGY1 managed care pharmacy residency program.
Hot Topics in Health Policy: Focus on Medicare Part D Redesign ad PBM ReformWith rising medical treatment costs and increased scrutiny of health care reimbursement and access, health policy is more important than ever. Two specific health policy topics warrant a comprehensive understanding for managed care professionals to plan and operationalize changes effectively in advance of 2025.
October 2024
Roundtable Discussion: Strategies for Optimal and Equitable Care in Lupus and Lupus Nephritis
A Science & Innovation Webinar, presented by GSK.
Lupus nephritis (LN) is a severe complication of lupus that may lead to significant chronic kidney disease and potentially end stage kidney disease (ESKD). African American Patients with LN are at a higher risk of developing ESKD. Early and accurate diagnosis and testing are key strategies in providing optimal patient care. Evaluation of the needs of the affected community through an interdisciplinary and integrated care management approach may address the gap in inequitable access to care. This presentation and roundtable discussion will be structured to help understand what strategies can be implemented to support patients that do not have access to optimal and equitable care.
October 2024
From LDL-C to Lp(a): Opportunities to Reduce the Rising Tide of Cardiovascular Disease
A Science & Innovation Webinar, presented by Family Heart Foundation.
The Family Heart Foundation is a non-profit organization dedicated to research, education, and advocacy, and as part of ongoing research efforts, has examined the state of LDL-C control among 38M Americans at high and very high-risk for cardiovascular disease in the proprietary Family Heart Database. This session will provide an update on current LDL-C treatment guidelines, Lp(a) screening recommendations, and key findings and insights from an analysis of the Family Heart database.
October 2024
Northeast AMCP 2024 Day of Education
Join Northeast AMCP and your peers at the 2nd Annual Day of Education in New York. You will hear perspectives and gain valuable insights from a variety of healthcare professionals representing various roles (e.g., Pharmacists, managed care leaders from PBMs, Health plans, and AMCP leaders). CE credits will be available.
October 2024
Chronic Hepatitis B: A Primer on Disease Burden to Support Population Planning
A Science & Innovation Webinar, presented by GSK.
Hepatitis B virus (HBV) is an infection that is transmitted from mother to child at birth or through exposure to infected blood and bodily fluids. Chronic hepatitis B (CHB) is a long-lasting infection that persists in the blood and liver that can lead to liver failure, cirrhosis, hepatocellular carcinoma (HCC), and death. CHB affects over 1 million Americans and disproportionately affects people from racial and ethnic minorities. Although chronic suppressive therapy exists, current limitations to the management of CHB include the inability to eliminate circulating HBV proteins and the risk of HCC completely.
Learning Objectives:
- Understand CHB and its epidemiology.
- Discuss the burden of CHB.
- Review the current management guidelines for CHB.
October 2024
Vertex Formulary Decision-Maker Webinar: Investigational Pain Program
A Pre-Approval Information Exchange (PIE) Webinar sponsored by Vertex Pharmaceuticals Incorporated.
Information about Vertex Investigational Pain Program, including:
An overview of Vertex’s commitment to patients, investigational pain research pipeline, and approach to developing pain treatments.
A breakdown of the current acute pain treatment landscape and some of the unmet needs that exist in acute pain management, along with an overview of societal and economic burden.
Data from Phase 3 studies in acute pain.
Anticipated commercial considerations for potential budgetary planning.
This event is intended to provide payers, formulary committees, and similar entities with general information about a Vertex investigational product. The information in this event is intended for formulary decision-makers and is being shared with you as part of your formulary decision-making process. This PIE Webinar meeting is organized and fully funded by Vertex Pharmaceuticals Incorporated.
This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
Members FREE Non-Members FREE